Numab Therapeutics

Numab is a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation.

Numab specializes in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.

Numab was co-founded in 2011 by David Urech, Oliver Middendorp, and Peter Lichtlen. The company is headquartered in Zurich, Switzerland.

 

Numab's plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.

 

Numab's pipeline was created using its antibody discovery and engineering MATCH platform that produces highly potent and stable antibody Fv fragments, fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind.

 

Numab's lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously.

 

Numab is backed by Novo Holdings, BlackRock, HBM Partners, Mitsubishi UFJ Capital, Forbion, 3SBio's Sunshine Guojian, Cormorant Asset Management, BVF Partners, Eisai Co., RTW Investments, Octagon Capital Advisors, and others. The company raised $111M (CHF100M) in a Series C round on May 20, 2021. This brings Numab's total funding to CHF122M ($150M) to date.

 

 

  • Year founded: 2011
  • Funding Info: CHF122M ($150M) over 3 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 501-1,000
  • Business Valuation: NA
  • City/Town: Zürich
  • State: Zürich
  • Country: Switzerland
Related businesses